| Autor: |
De Felice, F., Storci, G., Ricci, F., Tazzari, P. L., De Matteis, S., Bertuccio, S. N., Rossini, L., Tomassini, E., Dicataldo, M., Laprovitera, N., Barbato, F., Ursi, M., Messelodi, D., Cortelli, P., Guarino, M., Maffini, E., Roberto, M., Dan, E., Sinigaglia, B., Santi, S. |
| Předmět: |
|
| Zdroj: |
Hematological Oncology; Jun2023 Supplement S2, Vol. 41, p534-534, 1p |
| Abstrakt: |
B Introduction: b Immune effector cell-associated neurotoxicity syndrome (ICANS) is a life-threatening adverse effect of anti-CD19 chimeric antigen receptor (CAR) T-cell therapy that usually occurs within 5-7 days after cell infusion. Predicting ICANS by means of plasma CAR-T cell derived extracellular vesicles in patients undergoing infusion of anti-CD19 CAR-T cells Twenty out of 71 patients (28%) had ICANS of any grade: 5 patients (7%) ICANS grade 1, 7 patients (10%) ICANS grade 2 and 8 patients (11%) ICANS grade >=3 (3 patients ICANS grade 3, 3 patients ICANS grade 4 and 2 patients ICANS grade 5 with diffuse cerebral edema). [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text